AMPIO PHARMACEUTICALS, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2011-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.ampiopharma.com
A Study to Evaluate Ampion in Patients With Prolonged Respiratory Symptoms Due to COVID-19 (Long COVID)
Phase 1
Completed
- Conditions
- Covid19
- Interventions
- Biological: AmpionOther: Placebo
- First Posted Date
- 2021-05-10
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Ampio Pharmaceuticals. Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT04880161
- Locations
- 🇺🇸
Ampio Pharmaceuticals, Englewood, Colorado, United States
A Study of Inhaled Ampion in Adults With Respiratory Distress Due to COVID-19
Phase 2
Terminated
- Conditions
- Covid19
- Interventions
- Biological: AmpionOther: Placebo
- First Posted Date
- 2021-05-03
- Last Posted Date
- 2022-12-07
- Lead Sponsor
- Ampio Pharmaceuticals. Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT04868890
- Locations
- 🇺🇸
Ampio Pharmaceuticals, Englewood, Colorado, United States
Study of Intravenous Ampion in Adult COVID-19 Patients Requiring Supplemental Oxygen
Phase 2
Terminated
- Conditions
- COVID-19
- Interventions
- Biological: AmpionOther: Saline
- First Posted Date
- 2021-04-09
- Last Posted Date
- 2022-11-30
- Lead Sponsor
- Ampio Pharmaceuticals. Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT04839965
- Locations
- 🇺🇸
Ampio Pharmaceuticals, Englewood, Colorado, United States
Study of Nebulized Ampion for the Treatment of Adult COVID-19 Patients With Respiratory Distress
Phase 1
Completed
- Conditions
- Covid19
- Interventions
- Biological: AmpionOther: Standard of Care
- First Posted Date
- 2020-10-28
- Last Posted Date
- 2022-03-21
- Lead Sponsor
- Ampio Pharmaceuticals. Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT04606784
- Locations
- 🇺🇸
Research Site, Colorado Springs, Colorado, United States
Study of Ampion for the Treatment of Adult COVID-19 Patients Requiring Oxygen Supplementation
Phase 1
Completed
- Conditions
- COVID-19
- Interventions
- Biological: AmpionOther: Standard of Care
- First Posted Date
- 2020-07-02
- Last Posted Date
- 2021-01-13
- Lead Sponsor
- Ampio Pharmaceuticals. Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT04456452
- Locations
- 🇺🇸
Research Site, Colorado Springs, Colorado, United States
Study of Ampion for the Treatment of Pain and Function in Patients With Severe Osteoarthritis of the Knee.
Phase 3
Terminated
- Conditions
- Severe Osteoarthritis of the Knee
- Interventions
- Biological: AmpionDrug: Saline
- First Posted Date
- 2019-06-17
- Last Posted Date
- 2022-10-05
- Lead Sponsor
- Ampio Pharmaceuticals. Inc.
- Target Recruit Count
- 1043
- Registration Number
- NCT03988023
- Locations
- 🇺🇸
Denver Metro Orthopedics, Englewood, Colorado, United States
Open Label Extension to Assess the Safety of Long-Term Treatment With Ampion for Severe Osteoarthritis (OA) of the Knee
Phase 3
Terminated
- Conditions
- Severe Osteoarthritis of the Knee
- Interventions
- Biological: 4 mL injection of AMPION™
- First Posted Date
- 2017-11-21
- Last Posted Date
- 2022-10-03
- Lead Sponsor
- Ampio Pharmaceuticals. Inc.
- Target Recruit Count
- 94
- Registration Number
- NCT03349645
- Locations
- 🇺🇸
Heartland Research Associates, Wichita, Kansas, United States
🇺🇸Central Research Associates, Inc., Birmingham, Alabama, United States
🇺🇸St. Joseph Heritage, Fullerton, California, United States
AP-003-C Study to Confirm the Efficacy of Ampion™ in Adults With Pain Due to Severe Osteoarthritis of the Knee
Phase 3
Completed
- Conditions
- Knee OsteoarthritisKnee Pain ChronicOsteoarthritis, KneeKnee Arthritis
- Interventions
- Drug: 4 mL Injection of PlaceboBiological: 4 mL injection of Ampion
- First Posted Date
- 2017-06-09
- Last Posted Date
- 2022-08-09
- Lead Sponsor
- Ampio Pharmaceuticals. Inc.
- Target Recruit Count
- 168
- Registration Number
- NCT03182686
- Locations
- 🇺🇸
St. Joseph Heritage, Fullerton, California, United States
🇺🇸Westlake Medical Research, Thousand Oaks, California, United States
🇺🇸Central Research Associates, Inc., Birmingham, Alabama, United States
AP-011 Study to Evaluate the Safety of a Single Intra-articular Injection of Ampion™ for Arthritis of the Basal Thumb Joint
Phase 1
Completed
- Conditions
- Osteoarthritis of the Hand
- Interventions
- Biological: SalineBiological: AMPION™
- First Posted Date
- 2016-05-05
- Last Posted Date
- 2016-11-15
- Lead Sponsor
- Ampio Pharmaceuticals. Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT02762760
- Locations
- 🇺🇸
Ampio Pharmaceuticals, Englewood, Colorado, United States
A Study to Evaluate the Efficacy & Safety of an Intra-Articular Ampion Injection for Pain of Osteoarthritis of the Knee
Phase 3
Completed
- Conditions
- Osteoarthritis of the Knee
- Interventions
- Biological: 4 mL injection of AMPION™Drug: 4 mL injection of Placebo
- First Posted Date
- 2015-09-22
- Last Posted Date
- 2022-08-09
- Lead Sponsor
- Ampio Pharmaceuticals. Inc.
- Target Recruit Count
- 480
- Registration Number
- NCT02556710
- Locations
- 🇺🇸
Ampio Pharmaceuticals, Englewood, Colorado, United States
© Copyright 2025. All Rights Reserved by MedPath